CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathyCelia Cordero-Sánchez, Armando A. Genazzani|Blood Advances|2022Cited by 12
Performance of the accelerated assessment of the European Medicines AgencyVittorio Del Grosso, Armando A. Genazzani, Enrico Costa et al.|British Journal of Clinical Pharmacology|2025Cited by 4
Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational studyEnrico Costa, Lorenzo Moja, Vittorio Del Grosso et al.|Frontiers in Medicine|2025Cited by 2
L’accesso ai farmaci per malattie rare tra aspetti regolatori e priorità di salute pubblicaEnrico Costa, Armando A. Genazzani, Antonella Isgrò et al.|Recenti Progressi in Medicina|2022Cited by 1